Genetic imbalance related to cisplatin-based chemoresistance in epithelial ovarian cancer.
To identify genetic imbalance related to chemoresistance in epithelial ovarian cancer. We screened abnormal chromosomal regions in cisplatin-resistant and cisplatin-sensitive human ovarian cancer cell lines employing comparative genomic hybridization (CGH). We also documented non-random chromosome gains and losses with cisplatin-resistant and cisplatin-sensitive primary epithelial ovarian tumors from patients. There were extensive chromosome changes in cisplatin-resistant and cisplatin-sensitive cell lines. Gains of 1q12-22, 17q21-22 and loss of 3p21-24 were significantly more common in drug-resistant tumors from patients compared to the drug-sensitive group. The special chromosomal aberrances might provide us with a clue for further investigation of the dominant mechanism that leads to a drug-resistant phenotype.